Document is current
Any future updates will be listed below
-
Authors
Sivaramakrishnan, Manaswini
McCarthy, Kathleen D.
Campagne, Sébastien
Huber, Sylwia
Meier, Sonja
Augustin, Angélique
Heckel, Tobias
Meistermann, Hélène
Hug, Melanie N.
Birrer, Pascale
Moursy, Ahmed http://orcid.org/0000-0001-6523-3508
Khawaja, Sarah
Schmucki, Roland
Berntenis, Nikos
Giroud, Nicolas
Golling, Sabrina
Tzouros, Manuel
Banfai, Balazs http://orcid.org/0000-0003-0422-7977
Duran-Pacheco, Gonzalo
Lamerz, Jens
Hsiu Liu, Ying
Luebbers, Thomas
Ratni, Hasane
Ebeling, Martin
Cléry, Antoine
Paushkin, Sergey
Krainer, Adrian R.
Allain, Frédéric H.-T.
Metzger, Friedrich
- License Information
-
More Information
Article History
Received: 8 November 2016
Accepted: 27 September 2017
First Online: 14 November 2017
Competing interests
: M.S., K.D.M, S.H., S.M., A.A., T.H., H.M., M.N.H., P.B., R.S., N.B., N.G., S.G., M.T., B.B., G.D.-P., J.L., T.L., H.R., M.E., and F.M. are employees of Hoffmann-La Roche. Hoffmann-La Roche and PTC Therapeutics have filed three patent applications entitled “Compounds for Treating Spinal Muscular Atrophy” (WO2013/101974 A1, WO2013/112788 A1, and WO2013/119916 A2). The remaining authors declare no competing financial interests.
